SHR-4640
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- SHR-4640
- Molecular weight
- 338.23
- Structure (SMILES)
- O=C(O)C1(Sc2ccnc3ccc(Br)cc23)CCC1
- 1 6 bromo 4 quinolinyl thio cyclobutanecarboxylic acid
- 1-((6-BROMO-4-QUINOLINYL)THIO)CYCLOBUTANECARBOXYLIC ACID
- ruzinurad
- Ruzinurad
- ruzinurad [INN]
- Ruzinurad [WHO-DD]
- ruzinurad inn
- ruzinurad who dd
- shr 4640
- Shr-4640
- SHR-4640
- shr4640
- Shr4640
- SHR4640
- SHR4640 tablet
- CAS registry numbers
- 1638327-48-6
- ChEMBL ID
- CHEMBL3746329
- InChIKey
- QGBWIYLNOBYNDL-UHFFFAOYSA-N
- PubChem compound IDs
- 86294127
- FDA ingredient codes (UNII)
- UP8J9CA76I
- First in class
- No
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Solute carrier family 22 member 12 inhibitor
- Action type
- Inhibitor
- Target
- Solute carrier family 22 member 12
- Protein identifier
- Q96S37
Open Targets mechanisms
- Mechanism
- Solute carrier family 22 member 12 inhibitor
- Action type
- Inhibitor
- Target
- Solute carrier family 22 member 12
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Gout
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004274
- Subject identifier
- D006073
- Condition
- Hyperuricemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009104
- Subject identifier
- D033461
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004274
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009104
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005393
- Highest recorded phase
- 3
- NCT03015948
- NCT03131583
- NCT04052932
- NCT04956432
- NCT03185793
- NCT04157959
- NCT04180982
- NCT05954169
- NCT06168929
- NCT04305392
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 50.19
- Calculated partition coefficient (ALogP)
- 4.1
- Calculated partition coefficient (XLogP)
- 3.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 19
- Molecular formula
- C14H12BrNO2S
- Monoisotopic mass
- 336.97721
- Natural product
- No
- Recorded assays
- 54
- Active assays
- 5
Active assay types
- Confirmatory
These details could not be displayed.
Related records
Trials (20)
- A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
- A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia
- A Single Dose Study of SHR4640 in Healthy Male Volunteers
- A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout
- Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects
- Clinical Study of SHR4640 Tablets Combined With Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
- Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
- Drug Interaction Between SHR4640 Tablets and Furosemide Tablets in Healthy Volunteers (Single Center, Single Arm, Open, Self-control)
- Multiple Dose Study of SHR4640 in Healthy Subjects
- Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level
- Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
- Pharmacokinetics, Pharmacodynamics and Safety of SHR4640 in Patients With Hepatic Impairment
- PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval
- Single Dose Study of SHR4640 in Healthy Subjects
- Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers
- Study on the Food Effects of Oral SHR4640 Tablets in Healthy Volunteers
- Study to Evaluate the Mass Balance and Biotransformation of [14C]SHR4640 in Chinese Healthy Adult Male Volunteers.
- The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia
- The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout
- The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia
In development for (2)
- Gout Phase 3
- Liver disorder Phase 1
Targets (1)
- SLC22A12 Solute carrier family 22 member 12 inhibitor